Table 2.
Univariate analysis of prognostic factors of overall survival (n = 96)
| Variable | HR, 95 % CI | p value |
|---|---|---|
| Sex | 0.81 (0.43–1.55) | 0.534 |
| (male vs. female) | ||
| Age | 0.74 (0.39–1.41) | 0.342 |
| (>54 years vs. ≤54 years) | ||
| ECOG performance status | 3.24 (1.40–7.50) | 0.006 |
| (0–1 vs. 2–3) | ||
| No. of brain metastases | 1.41 (0.74–2.69) | 0.299 |
| (1–4 vs. >4) | ||
| Max size of brain lesions | 1.03 (0.67–1.76) | 0.763 |
| (<1 cm vs. >1 cm) | ||
| Location of brain lesions | 1.62 (0.98–2.73) | 0.267 |
| (Brain stem mets vs. Non–brain stem mets) | ||
| Other sites of metastatic disease | 3.89 (1.58–9.57) | 0.002 |
| (No vs. Yes) | ||
| EGFR mutation | 0.74 (0.39–1.40) | 0.351 |
| (Exon 19 vs. Exon 21) | ||
| First line systemic treatment | 2.43 (1.08–5.48) | 0.032 |
| (TKI vs. Chemotherapy) | ||
| Time of brain RT | 0.77 (0.50–1.19) | 0.246 |
| (First line vs. Delayed vs. No RT) |
Legend: Each variable was assessed first in univariate analysis, with P value <0.10 regarded as statistically significant. Instead of timing of brain radiotherapy (RT), only Eastern Cooperative Oncology Group (ECOG) performance status, other distant metastases and first line systemic treatment were significantly associated with the overall survival